The EU-funded POTENT project has been developing a new type of drug delivery system for glioblastoma, an aggressive form of brain cancer. It can considerably improve treatment outcomes for patients and increase their life expectancy. Clinical trials could start in 2 to 4 years, a step closer to making the system available for the patients that could most benefit from it.

Drug assessment for potential negative effects on patients’ hearts is a cost-intensive task, and it still occasionally fails to deliver on its promise. The EU-funded MAREP project has created a new laser-based technology that can streamline the drug development process. At the same time, it enhances patient safety which is a big plus for all citizens.